135 related articles for article (PubMed ID: 25352632)
1. Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.
Morrison VA
Clin Infect Dis; 2014 Nov; 59 Suppl 5():S360-4. PubMed ID: 25352632
[TBL] [Abstract][Full Text] [Related]
2. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
3. The impact of the host on fungal infections.
Perfect JR
Am J Med; 2012 Jan; 125(1 Suppl):S39-51. PubMed ID: 22196208
[TBL] [Abstract][Full Text] [Related]
4. Strategies in the management of alemtuzumab-related side effects.
Osterborg A; Karlsson C; Lundin J; Kimby E; Mellstedt H
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S29-35. PubMed ID: 16720201
[TBL] [Abstract][Full Text] [Related]
5. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients.
Swaika A; Paulus A; Miller KC; Sher T; Almyroudis NG; Ball D; Wood M; Masood A; Lee K; Chanan-Khan AA
J Support Oncol; 2012; 10(4):155-9. PubMed ID: 22222250
[TBL] [Abstract][Full Text] [Related]
6. [Infections in patients affected by rheumatologic diseases associated to glucocorticoid use or tumor necrosis factor-alpha inhibitors].
Fica A
Rev Chilena Infectol; 2014 Apr; 31(2):181-95. PubMed ID: 24878907
[TBL] [Abstract][Full Text] [Related]
7. [Infectious complications of biological therapy].
Holub M; Rozsypal H; Chalupa P
Klin Mikrobiol Infekc Lek; 2011 Feb; 17(1):24-9. PubMed ID: 21452120
[TBL] [Abstract][Full Text] [Related]
8. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
[TBL] [Abstract][Full Text] [Related]
9. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders.
Martin SI; Marty FM; Fiumara K; Treon SP; Gribben JG; Baden LR
Clin Infect Dis; 2006 Jul; 43(1):16-24. PubMed ID: 16758413
[TBL] [Abstract][Full Text] [Related]
10. [Aggravated post-herpetic neuralgia due to bortezomib].
Kirizume K; Imataki O; Shintani T; Fujihara S; Waki F; Ohue Y; Ohnishi H
Rinsho Ketsueki; 2008 May; 49(5):331-4. PubMed ID: 18572810
[TBL] [Abstract][Full Text] [Related]
11. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
Chanan-Khan A; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Neuwirth R; Anderson KC; Richardson PG
J Clin Oncol; 2008 Oct; 26(29):4784-90. PubMed ID: 18711175
[TBL] [Abstract][Full Text] [Related]
12. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.
Thursky KA; Worth LJ; Seymour JF; Miles Prince H; Slavin MA
Br J Haematol; 2006 Jan; 132(1):3-12. PubMed ID: 16371014
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib and bilateral herpes zoster.
di Meo N; Bergamo S; Dondas A; Trevisan G
Acta Dermatovenerol Alp Pannonica Adriat; 2012; 21(1):21-2. PubMed ID: 22584902
[TBL] [Abstract][Full Text] [Related]
14. Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections.
Moiton MP; Richez C; Dumoulin C; Mehsen N; Dehais J; Schaeverbeke T
Clin Microbiol Infect; 2006 Dec; 12(12):1151-3. PubMed ID: 17121619
[TBL] [Abstract][Full Text] [Related]
15. Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib.
Piro E; Kropp M; Cantaffa R; Lamberti AG; Carillio G; Molica S
Ann Hematol; 2012 Nov; 91(11):1827-8. PubMed ID: 22584850
[No Abstract] [Full Text] [Related]
16. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma.
Kim SJ; Kim K; Kim BS; Lee HJ; Kim H; Lee NR; Nam SH; Kwon JH; Kim HJ; Sohn SK; Won JH; Lee JH; Suh C; Yoon SS; Kim HJ; Kim I; Do YR; Lee WS; Joo YD; Shin HJ;
Clin Lymphoma Myeloma; 2008 Aug; 8(4):237-40. PubMed ID: 18765311
[TBL] [Abstract][Full Text] [Related]
17. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.
Tong Y; Qian J; Li Y; Meng H; Jin J
Am J Hematol; 2007 May; 82(5):403-4. PubMed ID: 17133426
[TBL] [Abstract][Full Text] [Related]
18. [Alteration in antibody-mediated immunity in patients with rituximab-combined chemotherapy and incidence of herpes zoster].
Ito K; Okamoto M; Maruyama F; Handa K; Yamamoto Y; Watanabe M; Tsuzuki M; Mizuta S; Kumazawa S; Ohta H; Nakano I; Emi N
Gan To Kagaku Ryoho; 2010 Jan; 37(1):99-102. PubMed ID: 20087040
[TBL] [Abstract][Full Text] [Related]
19. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases.
Cooper N; Arnold DM
Br J Haematol; 2010 Apr; 149(1):3-13. PubMed ID: 20151975
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib monotherapy in patients with multiple myeloma is associated with reactivation of hepatitis B.
Goldberg R; Smith E; Bell S; Thompson A; Desmond PV
Intern Med J; 2013 Jul; 43(7):835-6. PubMed ID: 23841765
[No Abstract] [Full Text] [Related]
[Next] [New Search]
